Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 2.5mg/mL (2-mL or 4-mL, single-dose vial)
Postoperative Nausea & Vomiting
Prevention
- Indicated for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class
- 5 mg as a single IV dose at time of anesthesia induction
Treatment
- Indicated for treatment of PONV in adults who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis
- 10 mg as a single IV dose in the event of nausea and/or vomiting postoperatively
Dosage Modifications
Renal impairment
- Mild-to-moderate (≥30 mL/min/1.73 m2): No dosage adjustment necessary
- Severe (<30 mL/min/1.73 m2): Avoid use; known to be substantially excreted by kidneys and patients with severe renal impairment may have increased systemic exposure and an increased risk of adverse reactions
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (26)
- aripiprazole
amisulpride, aripiprazole. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- asenapine
amisulpride, asenapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- brexpiprazole
amisulpride, brexpiprazole. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- cariprazine
amisulpride, cariprazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- chlorpromazine
amisulpride, chlorpromazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- clozapine
amisulpride, clozapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- dronedarone
amisulpride and dronedarone both increase QTc interval. Contraindicated.
- droperidol
amisulpride, droperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- fluphenazine
amisulpride, fluphenazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- haloperidol
amisulpride, haloperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- iloperidone
amisulpride, iloperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- loxapine
amisulpride, loxapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- loxapine inhaled
amisulpride, loxapine inhaled. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- lumateperone
amisulpride, lumateperone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- lurasidone
amisulpride, lurasidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- olanzapine
amisulpride, olanzapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- paliperidone
amisulpride, paliperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- perphenazine
amisulpride, perphenazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- pimozide
amisulpride and pimozide both increase QTc interval. Contraindicated.
amisulpride, pimozide. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome. - prochlorperazine
amisulpride, prochlorperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- quetiapine
amisulpride, quetiapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- risperidone
amisulpride, risperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- thioridazine
amisulpride and thioridazine both increase QTc interval. Contraindicated.
amisulpride, thioridazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome. - thiothixene
amisulpride, thiothixene. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- trifluoperazine
amisulpride, trifluoperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- ziprasidone
amisulpride, ziprasidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
Serious - Use Alternative (150)
- alfuzosin
amisulpride and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- amantadine
amisulpride, amantadine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- amiodarone
amiodarone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- apomorphine
amisulpride, apomorphine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
apomorphine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered. - arformoterol
arformoterol and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- aripiprazole
aripiprazole and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- arsenic trioxide
amisulpride and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- artemether
artemether and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
amisulpride and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- asenapine
amisulpride and asenapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- atomoxetine
atomoxetine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- azithromycin
amisulpride and azithromycin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- bedaquiline
amisulpride and bedaquiline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- bromocriptine
amisulpride, bromocriptine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- buprenorphine
amisulpride and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ceritinib
ceritinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- chloroquine
chloroquine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- chlorpromazine
chlorpromazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ciprofloxacin
amisulpride and ciprofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- citalopram
citalopram and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- clarithromycin
clarithromycin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- clozapine
clozapine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- crizotinib
crizotinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- dasatinib
dasatinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- degarelix
degarelix and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- desflurane
desflurane and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
amisulpride and desflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered. - deutetrabenazine
deutetrabenazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- disopyramide
amisulpride and disopyramide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- dofetilide
amisulpride and dofetilide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- dolasetron
amisulpride and dolasetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- donepezil
donepezil and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- droperidol
amisulpride and droperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- efavirenz
efavirenz and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- eliglustat
amisulpride and eliglustat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- encorafenib
encorafenib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- entrectinib
entrectinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- eribulin
eribulin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin base
amisulpride and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin ethylsuccinate
amisulpride and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin lactobionate
amisulpride and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin stearate
amisulpride and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- escitalopram
amisulpride and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fenoldopam
amisulpride, fenoldopam. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- fexinidazole
amisulpride and fexinidazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fingolimod
fingolimod and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- flecainide
amisulpride and flecainide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fluconazole
amisulpride and fluconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fluoxetine
amisulpride and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fluvoxamine
amisulpride and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- formoterol
amisulpride and formoterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- foscarnet
amisulpride and foscarnet both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fostemsavir
amisulpride and fostemsavir both increase QTc interval. Avoid or Use Alternate Drug. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gemifloxacin
gemifloxacin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- gemtuzumab
amisulpride and gemtuzumab both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- gilteritinib
amisulpride and gilteritinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- glasdegib
amisulpride and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- goserelin
amisulpride and goserelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- granisetron
amisulpride and granisetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- haloperidol
amisulpride and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- histrelin
amisulpride and histrelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- hydroxychloroquine sulfate
amisulpride and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- hydroxyzine
amisulpride and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ibutilide
amisulpride and ibutilide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- iloperidone
amisulpride and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- indacaterol, inhaled
amisulpride and indacaterol, inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- inotuzumab
amisulpride and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- isoflurane
amisulpride and isoflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- itraconazole
amisulpride and itraconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ivosidenib
amisulpride and ivosidenib both decrease QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lapatinib
amisulpride and lapatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lefamulin
amisulpride and lefamulin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lenvatinib
amisulpride and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- leuprolide
amisulpride and leuprolide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- levalbuterol
amisulpride and levalbuterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- levodopa
amisulpride, levodopa. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- levodopa inhaled
amisulpride, levodopa inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- levofloxacin
amisulpride and levofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- levoketoconazole
amisulpride and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- lithium
amisulpride and lithium both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
lithium and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. - lofexidine
amisulpride and lofexidine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- loperamide
amisulpride and loperamide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lopinavir
amisulpride and lopinavir both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- macimorelin
amisulpride and macimorelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- maprotiline
maprotiline and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mefloquine
amisulpride and mefloquine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- methadone
amisulpride and methadone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- midostaurin
amisulpride and midostaurin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mifepristone
amisulpride and mifepristone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mirtazapine
amisulpride and mirtazapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mobocertinib
amisulpride and mobocertinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- moxifloxacin
amisulpride and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- nilotinib
amisulpride and nilotinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- octreotide
amisulpride and octreotide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- octreotide (Antidote)
amisulpride and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ofloxacin
amisulpride and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- olanzapine
amisulpride and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances
- olodaterol inhaled
amisulpride and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ondansetron
amisulpride and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- osilodrostat
amisulpride and osilodrostat both increase QTc interval. Avoid or Use Alternate Drug. Dose dependent QT prolongation - avoid drugs known to prolong the QT interval
- osimertinib
amisulpride and osimertinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- oxaliplatin
amisulpride and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ozanimod
amisulpride and ozanimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- paliperidone
amisulpride and paliperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- panobinostat
amisulpride and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pasireotide
amisulpride and pasireotide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pazopanib
amisulpride and pazopanib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pentamidine
amisulpride and pentamidine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- perphenazine
perphenazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pimavanserin
amisulpride and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pitolisant
amisulpride and pitolisant both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ponesimod
amisulpride and ponesimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- posaconazole
amisulpride and posaconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pramipexole
amisulpride, pramipexole. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- primaquine
amisulpride and primaquine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- procainamide
amisulpride and procainamide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- promethazine
promethazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- propafenone
amisulpride and propafenone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- quetiapine
amisulpride and quetiapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- quinidine
quinidine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- quinine
amisulpride and quinine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ranolazine
amisulpride and ranolazine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- rilpivirine
amisulpride and rilpivirine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- risperidone
amisulpride and risperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- romidepsin
amisulpride and romidepsin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ropinirole
amisulpride, ropinirole. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- rotigotine
amisulpride, rotigotine. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- salmeterol
amisulpride and salmeterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- saquinavir
amisulpride and saquinavir both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- selpercatinib
amisulpride and selpercatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sertraline
amisulpride and sertraline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sevoflurane
amisulpride and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- siponimod
amisulpride and siponimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sorafenib
amisulpride and sorafenib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sotalol
amisulpride and sotalol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sunitinib
amisulpride and sunitinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- tacrolimus
amisulpride and tacrolimus both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- tetrabenazine
amisulpride and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- toremifene
amisulpride and toremifene both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- trazodone
trazodone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- triclabendazole
amisulpride and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- triptorelin
amisulpride and triptorelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- umeclidinium bromide/vilanterol inhaled
amisulpride and umeclidinium bromide/vilanterol inhaled both decrease QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vandetanib
amisulpride and vandetanib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vardenafil
amisulpride and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vemurafenib
amisulpride and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- venlafaxine
amisulpride and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vilanterol/fluticasone furoate inhaled
amisulpride and vilanterol/fluticasone furoate inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- voclosporin
amisulpride and voclosporin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vorinostat
amisulpride and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ziprasidone
amisulpride and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
Monitor Closely (20)
- albuterol
albuterol and amisulpride both increase QTc interval. Use Caution/Monitor.
amisulpride and albuterol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. - amitriptyline
amitriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
amisulpride and amitriptyline both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. - clofazimine
amisulpride and clofazimine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- clomipramine
clomipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- desipramine
desipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- doxepin
doxepin and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- ezogabine
amisulpride and ezogabine both increase QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed, particularly when dose titrated to 1200mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- fluphenazine
fluphenazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- gadobenate
gadobenate and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- imipramine
imipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- indapamide
amisulpride and indapamide both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- nortriptyline
nortriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- osilodrostat
osilodrostat and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- phenylephrine PO
amisulpride increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- prochlorperazine
prochlorperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- protriptyline
protriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- solifenacin
amisulpride and solifenacin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- telavancin
amisulpride and telavancin both increase QTc interval. Modify Therapy/Monitor Closely. ECG monitoring is recommended if coadministered.
- trifluoperazine
trifluoperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- trimipramine
trimipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
Minor (0)
Adverse Effects
1-10%
Prevention of PONV
- Increased blood prolactin (5%)
- Chills (4%)
- Hypokalemia (4%)
- Procedural hypotension (3%)
- Abdominal distension (2%)
Treatment of PONV
- Infusion site pain (6%)
Postmarketing Reports
Blood and lymphatic system disorders: Agranulocytosis
Cardiac disorders: Bradycardia, torsades de pointes, ventricular tachycardia, prolonged QT by ECG
General disorders: Neuroleptic malignant syndrome
Immune system disorders: Angioedema, hypersensitivity, urticaria
Hepatic disorders: Increased hepatic enzymes
Nervous system disorders: Agitation, anxiety, dystonia, extrapyramidal disorder, seizure
Psychiatric disorders: Confusional state, insomnia, somnolence
Vascular disorders: Hypotension
Warnings
Contraindications
Hypersensitivity
Cautions
QT prolongation
- May causes dose- and concentration-dependent prolongation of the QT interval
- Avoid in patients with congenital long QT syndrome and in patients taking droperidol
- ECG monitoring recommended with preexisting arrhythmias/cardiac conduction disorders, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), congestive heart failure, and in patients taking other drugs (eg, ondansetron) or with other medical conditions known to prolong the QT interval
Drug interactions overview
- Amisulpride inhibits MATE1 and MATE2-K transporters
- Amisulpride is a substrate for P-gp, BCRP, OCT1, MATE1, and MATE2-K
-
Dopamine agonists
- Reciprocal antagonism of effects occurs between dopamine agonists (eg, levodopa)
- Avoid use
-
Drugs prolonging the QT interval
- Amisulpride causes dose- and concentration-dependent QT prolongation
- Avoid use with droperidol
- ECG monitoring recommended if coadministered with other drugs known to prolong QT interval (eg, ondansetron)
Pregnancy & Lactation
Pregnancy
Insufficient data available regarding use in pregnant women to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Infertility
- In animal fertility studies, administration of repeated doses of amisulpride over a 10-day period to female rats resulted in infertility that was reversible
Lactation
Based on case reports in published literature, amisulpride is present in human milk at concentrations that are 11- to 20-fold higher than human plasma in patients taking multiple oral doses of amisulpride (200-400 mg/day)
There are no reports of adverse effects on breastfed children and no information on effects of amisulpride on milk production
May consider interrupting breastfeeding and pumping and discarding breast milk for 48 hr after administration to minimize drug exposure to a breastfed infant
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist
D2 receptors are located in the chemoreceptor trigger zone (CTZ) and respond to the dopamine released from the nerve endings
Activation of CTZ relays stimuli to the vomiting center, which is involved in emesis
Absorption
Peak plasma concentration
- Healthy subjects: 200 ng/mL (5 mg); 451 ng/mL (10 mg)
- Patients: 58-64 ng/mL (5 mg); 446 ng/mL (10 mg)
AUC
- Healthy subjects: 154 ng⋅hr/mL (5 mg); 136 ng⋅hr/mL (10 mg)
- Patients: 204-260 ng⋅hr/mL (5 mg); 401 ng⋅hr/mL (10 mg)
Distribution
Vd: 127-144 L (surgical patients); 171 L (healthy subjects)
Protein bound: 25-30%
Metabolism
No metabolites were detectable in plasma while 4 metabolites were identified in urine and feces
Each metabolite accounts for <7% of the dose
In vitro amisulpride is not metabolized by major cytochrome P450 enzymes
Elimination
Half-life: ~ 4-5 hr
Clearance: 20.6 hr (surgical patients); 24.1 L/hr (healthy subjects)
Renal clearance: 20.5 L/hr (healthy subjects)
Excretion: Urine (74% [58% unchanged]), feces (23% [20% unchanged])
Administration
IV Compatibilities
Sterile water for injection
Dextrose 5% (D5W)
0.9% NaCl
Lactated Ringer (LR)
IV Administration
Dilution not required
Infuse over 1-2 min
May flush IV line before or after administration with sterile water for injection, D5W, LR, or 0.9% NaCl
Storage
Protect from light
Unopened vials: Store at 20-25ºC (68-77ºF)
Open vials: Administer within 12 hr of removal of the vial from the protective carton
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.